Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AIO KRK-0114 / FIRE-4 Avelumab: Randomised study of the efficacy of cetuximab rechallenge in patients with RAS wild-type mCRC responding to an induction treatment in first-line with FOLFIRI plus cetuximab followed by a maintenance concept with either avelumab or 5-FU plus bevacizumab or continuation of FOLFIRI plus cetuximab

Next Previous
Trial Profile

AIO KRK-0114 / FIRE-4 Avelumab: Randomised study of the efficacy of cetuximab rechallenge in patients with RAS wild-type mCRC responding to an induction treatment in first-line with FOLFIRI plus cetuximab followed by a maintenance concept with either avelumab or 5-FU plus bevacizumab or continuation of FOLFIRI plus cetuximab

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Avelumab; Bevacizumab; Capecitabine; Fluorouracil; Folinic acid; Irinotecan; Regorafenib
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms AIO KRK-0114/FIRE-4 Avelumab; FIRE-4

Most Recent Events

  • 22 May 2025 According to a Merck and Co media release, a rapid oral presentation on the final analysis of this study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago.
  • 16 Apr 2025 Status changed from active, no longer recruiting to completed.
  • 13 Nov 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top